Free Trial

Jason N. Analyst Performance

Analyst at Citizens Jmp

Jason N. is a stock analyst at Citizens Jmp focused in the medical sector, covering 16 publicly traded companies. Over the past year, Jason N. has issued 21 stock ratings, including buy and hold recommendations. While full access to Jason N.'s proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Jason N.'s coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
21 Last 0 Years
Buy Recommendations
95.24% 20 Buy Ratings
Companies Covered
16 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy95.2%20 ratings
Hold4.8%1 ratings
Sell0.0%0 ratings

Out of 21 total stock ratings issued by Jason N. at Citizens Jmp, the majority (95.2%) have been Buy recommendations, followed by 4.8% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
93.8% of companies on NASDAQ
15 companies
NYSEAMERICAN
6.3% of companies on NYSEAMERICAN
1 company

Jason N., an analyst at Citizens Jmp, currently covers 16 companies listed on NASDAQ and NYSEAMERICAN, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
14 companies
87.5%
Miscellaneous
1 company
6.3%
Finance
1 company
6.3%

Jason N. of Citizens Jmp specializes in stock coverage within the Medical sector, with additional focus on and Finance companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
10 companies
62.5%
MED - DRUGS
4 companies
25.0%
Miscellaneous
1 company
6.3%
FIN - MISC SVCS
1 company
6.3%

Jason N.'s Ratings History at Citizens Jmp

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
CorMedix Inc stock logo
CRMD
CorMedix
4/28/2026Reiterated Rating$7.64$19.00Market Outperform
Precigen, Inc. stock logo
PGEN
Precigen
3/26/2026Boost Price Target$4.04$9.00Market Outperform
Nasus Pharma Ltd. stock logo
NSRX
Nasus Pharma
3/26/2026Lower Price Target$2.66$18.00Market Outperform
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
3/13/2026Boost Price Target$2.47$5.00Market Outperform
GH Research PLC stock logo
GHRS
GH Research
3/6/2026Boost Price Target$15.17$42.00Market Outperform
argenex SE stock logo
ARGX
argenex
2/27/2026Boost Price Target$771.53$944.00Market Outperform
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
2/26/2026Boost Price Target$3.67$10.00Market Outperform
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
2/26/2026Boost Price Target$23.80$35.00Market Outperform
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
2/3/2026Reiterated Rating$26.13$34.00Market Outperform
Rezolute, Inc. stock logo
RZLT
Rezolute
12/11/2025Downgrade$1.80Hold
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
11/25/2025Initiated Coverage$3.97$19.00Market Outperform
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
11/7/2025Boost Price Target$25.12$80.00Market Outperform
TeraWulf Inc. stock logo
WULF
TeraWulf
10/29/2025Boost Price Target$15.55$22.00Market Outperform
Rezolute, Inc. stock logo
RZLT
Rezolute
10/29/2025Boost Price Target$9.54$17.00Market Outperform
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
9/25/2025Boost Price Target$82.55$114.00Market Outperform
CorMedix Inc stock logo
CRMD
CorMedix
9/9/2025Reiterated Rating$12.75$22.00Market Outperform
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
9/2/2025Reiterated Rating$47.43$78.00Market Outperform
Precigen, Inc. stock logo
PGEN
Precigen
8/19/2025Boost Price Target$2.95$8.00Market Outperform
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
8/13/2025Lower Price Target$9.25$18.00Market Outperform
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
8/7/2025Boost Price Target$23.80$38.00Market Outperform
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
8/6/2025Boost Price Target$64.95$91.00Market Outperform